Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of 5 mg apixaban film-coated tablets under fasting conditions
TCTR20200814003Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of apixaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by Novartis. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20200814003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200814003.